Although we found that in vivo modulator use coincided with significantly lower transferrin (P = 0.0076) in activated, modulator-pretreated CF MDMs (Supplementary Fig. S3g), TfR1 protein expression was not altered in association with patient modulator use under any treatment conditions (Supplementary Fig. S4a,b). Here, TFRC is linked to cystic fibrosis.